ANI Pharmaceuticals EBITDA vs. Shares Owned By Insiders
| ANIP Stock | USD 60.19 0.38 0.64% |
EBITDA | First Reported 2010-12-31 | Previous Quarter 122.6 M | Current Value 128.7 M | Quarterly Volatility 50.6 M |
For ANI Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ANI Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ANI Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ANI Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ANI Pharmaceuticals over time as well as its relative position and ranking within its peers.
ANI |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ANI Pharmaceuticals. If investors know ANI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ANI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 13.824 | Earnings Share (0.47) | Revenue Per Share | Quarterly Revenue Growth 0.125 | Return On Assets |
The market value of ANI Pharmaceuticals is measured differently than its book value, which is the value of ANI that is recorded on the company's balance sheet. Investors also form their own opinion of ANI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ANI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ANI Pharmaceuticals' market value can be influenced by many factors that don't directly affect ANI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ANI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ANI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ANI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ANI Pharmaceuticals Shares Owned By Insiders vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ANI Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare ANI Pharmaceuticals value to that of its competitors to determine the firm's financial worth. ANI Pharmaceuticals is rated below average in ebitda category among its peers. It is rated below average in shares owned by insiders category among its peers . The ratio of EBITDA to Shares Owned By Insiders for ANI Pharmaceuticals is about 10,113,786 . At this time, ANI Pharmaceuticals' EBITDA is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value ANI Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.ANI Shares Owned By Insiders vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
ANI Pharmaceuticals |
| = | 106.6 M |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
ANI Pharmaceuticals |
| = | 10.54 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
ANI Shares Owned By Insiders Comparison
ANI Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers.
ANI Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ANI Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ANI Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of ANI Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of ANI Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 8 M | 8.4 M | |
| Operating Income | 54 M | 56.7 M | |
| Net Income | 16.9 M | 17.7 M | |
| Income Tax Expense | 1.3 M | 1.3 M | |
| Income Before Tax | 22.9 M | 24 M | |
| Total Other Income Expense Net | -31.2 M | -32.7 M | |
| Net Income From Continuing Ops | 12 M | 12.6 M | |
| Non Operating Income Net Other | 770.5 K | 809 K | |
| Net Loss | -44.6 M | -42.3 M | |
| Interest Income | 14.9 M | 13.7 M | |
| Net Interest Income | -25.8 M | -27.1 M | |
| Change To Netincome | 288.9 K | 274.5 K | |
| Net Income Per Share | 0.94 | 0.99 | |
| Income Quality | 7.28 | 7.65 | |
| Net Income Per E B T | 0.85 | 0.50 |
ANI Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ANI Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ANI Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ANI Pharmaceuticals' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in ANI Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Correlation Analysis Now
Correlation AnalysisReduce portfolio risk simply by holding instruments which are not perfectly correlated |
| All Next | Launch Module |
Use Investing Themes to Complement your ANI Pharmaceuticals position
In addition to having ANI Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Market ETFs Thematic Idea Now
Broad Market ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Market ETFs theme has 70 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Market ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.